Spotlight

UCL Enterprise Annual Review 2013/2014

Welcome to the third full year of the delivery phase of UCL’s enterprise strategy. As anticipated, our community continues to strive for excellence and that approach and commitment is clearly working. From working with corporations to assisting student entrepreneurs and spinning out research, We hope that you will enjoy reading about all our enterprise activities from across the university in this Annual Review for 2013/2014.

Professor Stephen Caddick
Vice-Provost (Enterprise and London)

Read the UCL Enterprise Annual Review



follow us on twitter


UCL ranked number one collaborator in the UK for biomedical industry partnerships

23 May 2013

UCL has ranked the leading institution in the UK as a partner for industry  within the biotechnology and pharmaceutical sectors compiled by the Nature Biotechnology journal.

UCL was ranked the top university in the UK and third in the world  – ranking only behind Harvard University and the University of Texas in the US – for partnerships including Ark Therapeutics, Eisai, Oxford Pharmascience and Horizon Discovery.

Of the 387 public-private partnerships analysed by the journal across a range of institutions, cancer and infectious diseases were the most significant areas of interest, followed by diagnostics.

“Our placing in this ranking is testament to the strong emphasis UCL has put on building strong relationships with industry for many years now, with our efforts accelerating with the implementation of a comprehensive enterprise strategy,” said Professor Stephen Caddick, Vice-Provost for Enterprise at UCL.

“The quality of research in the biomedical sciences emerging from UCL is world-leading, and this, too, has made us a natural choice for attracting partners looking to work with us to ensure such innovations benefit patients directly,” he added.